Related Experiment Video
Updated: Feb 4, 2026
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.5K
Chemotherapy-related Cardiomyopathy
Susan E Piper1, Theresa A McDonagh1
1King's College London, The James Black Centre, London, UK; Kings College Hospital NHS Foundation Trust, London, UK.
European Cardiology
|October 13, 2018
Summary
Chemotherapy improves cancer survival but can cause heart failure, particularly left ventricular systolic dysfunction. This review covers anthracyclines and trastuzumab, common culprits of cancer treatment-related cardiac toxicity.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Chemotherapeutic advances have improved cancer survival rates.
- Cardiac toxicity is a significant cause of morbidity in cancer survivors.
- Heart failure and left ventricular systolic dysfunction are common manifestations of cardiotoxicity.
Purpose of the Study:
- To review current opinions and guidelines on cancer treatment-induced cardiotoxicity.
- To focus on anthracyclines and trastuzumab as common cardiotoxic agents.
- To discuss the management of chemotherapy-related cardiac dysfunction.
Main Methods:
- Literature review of current opinions and guidelines.
- Focus on specific chemotherapeutic agents: anthracyclines and trastuzumab.
- Discussion of clinical manifestations and management strategies.
Main Results:
- Anthracyclines and trastuzumab are associated with significant cardiac toxicity.
- Cardiotoxicity can manifest as heart failure and left ventricular systolic dysfunction.
- Early detection and management are crucial for mitigating cardiac damage.
Conclusions:
- Cancer treatment-related cardiotoxicity is a growing clinical concern.
- Understanding the mechanisms and risks of agents like anthracyclines and trastuzumab is vital.
- Adherence to guidelines and proactive monitoring can improve outcomes for cancer patients.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
568
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
490
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
538
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
01:29Cardiomyopathy V: Interprofessional Care
442
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442
01:25Cardiomyopathy I: Introduction and Classification
605
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
605
01:29Cardiomyopathy VI: Nursing Management
356
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
356